Oral Lichenoid Reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings

Por Sibaud, V., Eid, C., Belum, VR., Combemale, P., Barres, B., Lamant, L., Mourey, L., Gomez-Roca, C., Estilo, CL., Motzer, R., Vigarios, E., Lacouture, Mario E.
Publicado no J Eur Acad Dermatol Venereol (2017)

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

Por Ott, P. A., Piha-Paul, S. A., Munster, P., Pishvaian, M. J., van Brummelen, E. M. J., Cohen, R. B., Gomez-Roca, C., Ejadi, S., Stein, M., Chan, E., Simonelli, M., Morosky, A., Saraf, S., Emancipator, K., Koshiji, M., Bennouna, J.
Publicado no Ann Oncol (2017)

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Por Gyawali, B., de Vries, E.G.E., Dafni, U., Amaral, T., Barriuso, J., Bogaerts, J., Calles, A., Curigliano, G., Gomez-Roca, C., Kiesewetter, B., Oosting, S., Passaro, A., Pentheroudakis, G., Piccart, M., Roitberg, F., Tabernero, J., Tarazona, N., Trapani, D., Wester, R., Zarkavelis, G., Zielinski, C., Zygoura, P., Cherny, N.I.
Publicado no ESMO Open (2021)